Timothy Campbell
Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
CAR-T cell therapy research, Multiple Myeloma Research and Treatments, Health Systems, Economic Evaluations, Quality of Life, Cancer Genomics and Diagnostics, Radiopharmaceutical Chemistry and Applications
Most-Cited Works
- → Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma(2021)2,301 cited
- → Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma(2019)1,689 cited
- → Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist(2005)1,093 cited
- → Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities(2015)412 cited
- → Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma(2021)391 cited
- → Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis(2012)222 cited
- → Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.(2020)120 cited
- → Inhibition of CD26 in Human Cord Blood CD34 + Cells Enhances Their Engraftment of Nonobese Diabetic/Severe Combined Immunodeficiency Mice(2007)110 cited
- → Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial(2023)107 cited
- → AMD3100 and CD26 Modulate Mobilization, Engraftment, and Survival of Hematopoietic Stem and Progenitor Cells Mediated by the SDF‐1/CXCL12‐CXCR4 Axis(2007)92 cited